DE69434582D1 - Die relulation der antigenpräsentation - Google Patents

Die relulation der antigenpräsentation

Info

Publication number
DE69434582D1
DE69434582D1 DE69434582T DE69434582T DE69434582D1 DE 69434582 D1 DE69434582 D1 DE 69434582D1 DE 69434582 T DE69434582 T DE 69434582T DE 69434582 T DE69434582 T DE 69434582T DE 69434582 D1 DE69434582 D1 DE 69434582D1
Authority
DE
Germany
Prior art keywords
relulation
antigen presentation
antigen
presentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434582T
Other languages
English (en)
Other versions
DE69434582T2 (de
Inventor
Robert E Humphreys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Application granted granted Critical
Publication of DE69434582D1 publication Critical patent/DE69434582D1/de
Publication of DE69434582T2 publication Critical patent/DE69434582T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
DE69434582T 1993-05-19 1994-05-18 Die regulation der antigenpräsentation Expired - Lifetime DE69434582T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64400 1993-05-19
US08/064,400 US5559028A (en) 1993-05-19 1993-05-19 Methods of enhancing or antigen presentation to T cells inhibiting
PCT/US1994/005617 WO1994026773A1 (en) 1993-05-19 1994-05-18 Regulation of antigen presentation

Publications (2)

Publication Number Publication Date
DE69434582D1 true DE69434582D1 (de) 2006-01-26
DE69434582T2 DE69434582T2 (de) 2006-10-26

Family

ID=22055708

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434582T Expired - Lifetime DE69434582T2 (de) 1993-05-19 1994-05-18 Die regulation der antigenpräsentation

Country Status (6)

Country Link
US (1) US5559028A (de)
EP (1) EP0702692B1 (de)
JP (2) JP3534761B2 (de)
CA (1) CA2163196C (de)
DE (1) DE69434582T2 (de)
WO (1) WO1994026773A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995030746A1 (en) * 1994-05-10 1995-11-16 The General Hospital Corporation Antisense inhibition of hepatitis c virus
US6509165B1 (en) * 1994-07-08 2003-01-21 Trustees Of Dartmouth College Detection methods for type I diabetes
WO1997010335A1 (de) * 1995-09-14 1997-03-20 Universität Tübingen Rekombinantes polypeptid basierend auf der primärsequenz der invarianten kette mit mindestens einer primärsequenz von einem spezifischen t-zellepitop oder eines proteinderivats und dieses rekombinante polypeptid kodierende nukleinsäuren
ES2208898T5 (es) * 1996-04-22 2009-04-16 Massachusetts Institute Of Technology Supresion de la respuesta inmune a traves de la inhibicion de la catepsina s.
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
AU6336398A (en) * 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
WO2000012698A1 (en) * 1998-08-31 2000-03-09 Astrazeneca Ab Human deltex-like gene zdx
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2002055726A2 (en) * 2000-10-31 2002-07-18 Gen Hospital Corp Detection and alteration of mhc class ii presentation phenotypes
CA2455915C (en) * 2001-03-29 2013-05-14 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
EP1556072B1 (de) * 2002-09-17 2010-05-19 Antigen Express, Inc. Ii-key/antigene epitop-hybrid-peptid-vakzine
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
JP5707326B2 (ja) * 2008-09-02 2015-04-30 アンティジェン・エクスプレス・インコーポレーテッドＡｎｔｉｇｅｎ Ｅｘｐｒｅｓｓ，Ｉｎｃ． ヒトパピローマウイルス／Ｉｉ−ｋｅｙのハイブリッドおよびその使用方法
EP2865387B1 (de) * 2008-11-21 2019-06-12 Københavns Universitet (University Of Copenhagen) Priming einer Immunantwort
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker

Also Published As

Publication number Publication date
CA2163196A1 (en) 1994-11-24
JP2004161777A (ja) 2004-06-10
EP0702692B1 (de) 2005-12-21
JP4019040B2 (ja) 2007-12-05
EP0702692A4 (de) 1998-06-10
DE69434582T2 (de) 2006-10-26
CA2163196C (en) 2008-02-12
JPH09509561A (ja) 1997-09-30
JP3534761B2 (ja) 2004-06-07
WO1994026773A1 (en) 1994-11-24
US5559028A (en) 1996-09-24
EP0702692A1 (de) 1996-03-27

Similar Documents

Publication Publication Date Title
DE69434582D1 (de) Die relulation der antigenpräsentation
FI935495A (fi) Näyttöjärjestely
DE69316010D1 (de) Anzeige
DK0687400T3 (da) Transducer
DE69324988T2 (de) Überprüfung des Sprechers
BR9406795A (pt) Transdutor
DE59303655D1 (de) Messwandler
DE9208632U1 (de) Display
KR950005362U (ko) 김밥 성형 장치
FI931805A0 (fi) Form foer framstaellning av betongelement
KR970046202U (ko) 오디오 콤포넌트의 작동 표시 장치
KR950005495U (ko) 조립식 가구
KR950009111U (ko) 거푸집 조임구
DE9318396U1 (de) Präsentationsständer
DE29511974U1 (de) Präsentationseinrichtung
FI930700A0 (fi) Anordningar foer avlaegsnande av goedsel
BR7201718U (pt) Display
ITVI930081A0 (it) Anello ornamentale
FI932785A0 (fi) Foerfarande foer framstaellning av aktivt kol av fibrer
KR930024237U (ko) 대금의 구조
FI91620B (fi) Kalvorakenne
UA328S (uk) Роздрібнювач
DE9209072U1 (de) Präsentationsständer
ITMI931237A0 (it) Anello
DE9316751U1 (de) Präsentationsvorrichtung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition